The board of directors approved the second amended and restated bylaws, effective immediately, establishing a classified board structure. Directors are divided into three equal classes with staggered three-year terms expiring at the 2026, 2027, and 2028 annual meetings respectively. The filing also updates corporate governance policies to reflect this change. Ainos operates in the biotechnology sector.
